Q1 2010 Results Conference Call 11 May 2010
Participants can access the conference under the following telephone numbers:
- Date: 11 May, 2010
- Time: 3pm CET (9am EST)
- Dialin numbers: 0800 10 12 072 (Germany) / 0800 358 0886 (UK) / +1 877 941 8633 (USA) / +49 6958 999 0806 (other countries)
- Conference ID: 4293702
Approximately two hours after the live presentation, an audio replay of the conference will be available on the "investors" section of the homepage www.4sc.com.
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proofofconcept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
4SC was founded in 1997, has 91 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.